Introduction {#sec1}
============

Systemic lupus erythematosus (SLE) is a common chronic multi-system autoimmune disorder of unknown etiology causing injury to many organ systems. It predominantly affects young women. SLE affects 40-200 per 100 000 persons \[[@cit0001]\], with the higher values seen in black populations. Cardiac manifestations develop in the majority of patients with SLE at some time during the course of their disease \[[@cit0001]\]. Cardiac involvements in SLE are: valvular disease, most often mitral regurgitation and usually hemodynamically insignificant; pericardial disease, usually an asymptomatic effusion; myocardial dysfunction and coronary artery disease \[[@cit0002]\]. Current diagnostic methods in particular echocardiography allows early diagnosis of non-coronary cardiac manifestations of systemic lupus erythematosus.

Methods {#sec2}
=======

The aim of our study was to assess the cardiac abnormalities in SLE patients, the contribution of echocardiography in this disease and to compare the 2 groups of patients with and without non-coronary cardiac manifestations. We have performed a transversal, descriptive study of SLE patients hospitalized in the Internal Medicine Department at the Military Hospital of Tunis between January 2016 and June 2018. Diagnosis of SLE was made according to the criteria of the American college of rheumatology (ACR). All patients underwent a cardiac ultrasound externally or during their stay in our department.

Results {#sec3}
=======

The patients were 61 females and 19 males (sex-ratio=3) with a mean age of 38 years. We divided the workforce into two groups according to the presence or absence of cardiac manifestations: group 1 (patients with cardiac disease) and group 2 (patients without cardiac disease. The clinical features of the patients of group 1 are summarized in [Table 1](#t0001){ref-type="table"}. Forty-two patients had cardiac involvement (Group 1). They were 33 females and 9 males with a mean age of the disease of 31,8 years (16-80 years) at the beginning of the disease and 41 years at the time of the study. In group 1, 83% were symptomatic. The symptoms were dominated by objectified chest pain (43%). In Doppler echocardiography, pericarditis was found in 23 patients (55%) with a single case of cardiac tamponade. Libman Saks endocarditis and lupus myocarditis were found in one case each. Pulmonary hypertension (HTP) was observed in 16 patients (38%) and valvular disease in 22 patients (52%). Cardiomegaly was observed in 9 patients (21%). Electrical abnormalities were dominated by micro-voltage found in 8 patients. The general symptoms (83%), skin lesions (76%) and musculoskeletal involvement (64%) were the most frequent events associated with the cardiac manifestations in group 1 ([Table 1](#t0001){ref-type="table"}). ANA were positive in 97% of cases and antiphospholipid antibodies in 24%. Prednisone: 1mg/kg/day and immunosuppressive therapy were indicated respectively in 71% and 38% of patients of group 1. The comparative study of the two groups showed that patients with pleural effusion (45 vs 15%) were more vulnerable to cardiac involvement (P=0.004) as well as renal impairment (57 vs 44%) but the difference, however, was not statistically significant here (p\>0.05). Rnp antibodies was higher in group 1 and statistically significant (p\<0,05). Some antibodies, and antiphospholipid antibodies were higher in group 1 but the difference was not statistically significant here (p\>0.05). Active disease with low complement (80%) was associated with higher frequency of cardiac involvement than disease in remission (62%) but the result was not statistically significant (p=0.07) ([Table 2](#t0002){ref-type="table"}).

###### 

Clinical features of patients with cardiac manifestations

  Clinical features          Patients (n=42)                     n (%)
  -------------------------- ----------------------------------- ----------
  general signs                                                  15 (36%)
  Reached mucocutaneous      Photosensitivity                    16 (38%)
  Nasal ulcerations          2 (5%)                              
  malar rash                 13 (31%)                            
  joint damage               arthralgia                          19 (45%)
  arthritis                  8 (19%)                             
  Deformation hand Jaccoud   1 (2%)                              
  renal impairment           Glomerular nephropathy              18 (43%)
  Renal Insufficiency        10 (24%)                            
  Serositis                  pleurisy                            13 (31%)
  ascites                    5 (12%)                             
  lung disease               diffuse infiltrative lung disease   5 (12%)
  achieved hematologic       neutropenia                         5 (12%)
  thrombopenia               5 (12%)                             
  Heamolytic anemia          6 (14%)                             
  neurological impairment    reached parenchymal                 6 (14%)
  Events thromboembolic      Thrombosis of the lower limbs       2 (5%)
  pulmonary embolism         2 (5%)                              
  lupus myositis                                                 1 (2,3%)
  hepatitis lupus                                                1 (2,3%)

###### 

Comparison of patients with and without cardiac manifestations

                                Group 1 n (42)   Group 2 n (38)   P
  ----------------------------- ---------------- ---------------- -------
  Sex (female)                  34               32               0.70
  General signs                 35               29               0.43
  Skin involvement              33               29               0.81
  Musculoskeletal involvement   27               24               0.91
  Achieved hematologic          27               25               0.88
  Serositis: pleural effusion   19               6                0.004
  Renal impairment              24               17               0.26
  Neurological involvement      6                6                0.85
  Ac anti DNA natifs            29               26               0.95
  Low complement                34               24               0.07
  Ac anti Sm                    9                4                0.18
  Ac anti Rnp                   8                1                0.03
  Ac antiphospholipid           10               4                0.11
  Corticosteroids1mg/kg/j       30               28               0.82
  Cyclophosphamide              16               15               0.89

Discussion {#sec4}
==========

Cardiovascular abnormalities are common in patients with systemic lupus erythematosus \[[@cit0003]\]. SLE is among systemic diseases most providers of heart disease \[[@cit0004], [@cit0005]\]. It probably develops in nearly all patients suffering from SLE at some time during the course of their disease. All components of the heart can be affected and venous thrombo-embolic complications may cause pulmonary hypertension and right heart failure \[[@cit0006]\]. Cardiac disease is observed in 30 to 62% by clinical, ultrasound or autopsy diagnostic tool \[[@cit0007], [@cit0008]\]. Its prevalence was 52% in our study, it was 70% in the French study of Badoui *et al* \[[@cit0009]\] and in 68% in the Polish study of Ostanek *et al* \[[@cit0010]\]. Pericardial involvement is the most common echocardiographic lesion in systemic lupus erythematosus (SLE) and is the most frequent cause of symptomatic cardiac disease. It is observed in 11 to 54% of the cases \[[@cit0007]\]. In our study, the frequency of pericarditis was 55% higher than those described in the recent studies. Tamponade occurs in less than 2% and constrictive pericarditis is extremely rare \[[@cit0001], [@cit0002]\]. Cardiac involvement may precede the clinical signs of lupus and it is usually asymptomatic. It is generally diagnosed by echocardiography performed for some other reason, such as suggestive electrocardiographic abnormalities. Pericarditis, as with other types of serositis, most often occurs when SLE is active in other organs as well. In our experience, patients with pleural effusion (45 vs 15%) were more vulnerable to cardiac involvement (P=0.004). Cardiomyopathy is uncommon clinically but autopsy studies found myocardial involvement in 40-50% of patients \[[@cit0001]\]. Valvular disease is often underdiagnosed because most of the time they are asymptomatic. Pulmonary arterial hypertension (PAH) is a rare complication of systemic lupus erythematosus (SLE) \[[@cit0009]\]. Its prevalence depends on the method with which it is diagnosed and the tools used for that (echocardiography or heart catheterism). This prevalence varies from 4.2 to 17.5% in the literature when diagnosed by echocardiography and from 0.5 to 9.3% using the right heart catheterism. In our patients, where PAH was defined by a systolic pulmonary arterial hypertension ≥ 30 mmHg in echocardiography, its prevalence was of 38% higher than those of the literature.

Conclusion {#sec5}
==========

Cardiac abnormalities are very common in lupus patients even when clinically asymptomatic. Echocardiography is an excellent non-invasive tool for cardiac evaluation. Their research must be systematic with echocardiography in order to reduce subsequent cardiac morbidity and mortality among the lupus patients.

What is known about this topic {#sec5.1}
------------------------------

-   Cardiovascular abnormalities are common in patients with systemic lupus erythematosus;

-   Cardiomyopathy is uncommon clinically but autopsy studies found myocardial involvement.

What this study adds {#sec5.2}
--------------------

-   This study was designed to assess cardiac abnormalities in patients with SLE by echocardiography and to compare the 2 groups of patients with and without cardiac manifestations;

-   Echocardiography is an excellent non-invasive tool for cardiac evaluation even when clinically asymptomatic.
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